Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, announces that it has entered into a termination agreement with Pharma Two B Ltd. which terminates the merger agreement between the two parties that was previously entered into on July 19, 2024.
Read the full article: Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. //
Source: https://www.globenewswire.com/news-release/2024/12/11/2995333/0/en/Hepion-Pharmaceuticals-Inc-Announces-Termination-of-Merger-Agreement-with-Pharma-Two-B-Ltd.html